A Phase 3 interventional study of Aripiprazole (Fixed dose) and Aripiprazole (Titrated dose) in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 2 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 10th registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–55
Xinyu Zhou · Sites in China
Ages 12–17
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 586 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 173 across the 33 interventional studies. Of the 27 that completed or were terminated, 17 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 15th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2009, is one of 23 in phase 3, and was the 6th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
1 of the studies testing aripiprazole in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) in patients with major depressive disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose
Drug: Aripiprazole (Fixed dose)
Titration dose
Drug: Aripiprazole (Titrated dose)
Placebo
Drug: Placebo
administered orally once daily, 3 mg daily, 6 weeks
Also known as: Aripiprazole
administered orally once daily, 3 to 15 mg daily, 6 weeks
Also known as: Aripiprazole
administered orally once daily, 6 weeks
Also known as: Placebo of aripiprazole
Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts
Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
MADRS Response Rate
The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).
Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
Mean Change in Sheehan Disability Scale (SDISS)
The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).
Time frame: Baseline (the end of the SSRI/SNRI treatment period), at completion of administration
| Milestone | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| Started | 194 | 197 | 195 |
| Completed | 177 | 180 | 183 |
| Not completed | 17 | 17 | 12 |
| Withdrew: Adverse event | 7 | 8 | 2 |
| Withdrew: Withdrawal by subject | 4 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 4 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Diabetic glucose level or hba1c>=6.5% | 0 | 1 | 1 |
| Withdrew: Change of residence or other commitments | 2 | 2 | 3 |
The change in MADRS total score from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period by covariance analysis, and compared the aripiprazole variable dose group with the placebo group as well as the aripiprazole fixed dose group with the placebo group. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts
| Rating score | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -9.6 ± 0.6 | -10.5 ± 0.6 | -7.4 ± 0.6 |
The percentage of subjects with a decrease in MADRS total score of 50% or more, from the end of the SSRI/SNRI treatment period to the end of the placebo-controlled, double-blind treatment period (or withdrawal).
| percentage of subjects | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| MADRS Response Rate | 39.2 | 42.1 | 28.2 |
The endpoint evaluated the change in SDISS from the end of the SSRI/SNRI treatment period to Week 6 of the placebo-controlled, double-blind treatment period. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).
| Rating score | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| Mean Change in Sheehan Disability Scale (SDISS) | -1.03 ± 0.11 | -0.96 ± 0.11 | -0.46 ± 0.11 |
Collected over 6 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Variable Dose Group of Aripiprazole | — | 3/194 (1.5%) | 140/194 (72.2%) |
| Fixed Dose Group of Aripiprazole | — | 2/197 (1%) | 122/197 (61.9%) |
| Placebo Group | — | 2/195 (1%) | 92/195 (47.2%) |
| Event | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| Malignant MelanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/194 | 0/197 | 0/195 |
| Major DepressionPsychiatric disorders | 1/194 | 0/197 | 0/195 |
| Suicide AttemptPsychiatric disorders | 1/194 | 1/197 | 1/195 |
| ContusionInjury, poisoning and procedural complications | 0/194 | 0/197 | 1/195 |
| Head InjuryInjury, poisoning and procedural complications | 0/194 | 0/197 | 1/195 |
| Ligament SprainInjury, poisoning and procedural complications | 0/194 | 0/197 | 1/195 |
| Post-Traumatic Neck SyndromeInjury, poisoning and procedural complications | 0/194 | 0/197 | 1/195 |
| Traffic AccidentInjury, poisoning and procedural complications | 0/194 | 0/197 | 1/195 |
| Haemorrhage SubcutaneousSkin and subcutaneous tissue disorders | 0/194 | 0/197 | 1/195 |
| Back PainMusculoskeletal and connective tissue disorders | 0/194 | 1/197 | 0/195 |
| Event | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group |
|---|---|---|---|
| AkathisiaNervous system disorders | 71/194 | 28/197 | 8/195 |
| NasopharyngitisInfections and infestations | 31/194 | 30/197 | 28/195 |
| TremorNervous system disorders | 20/194 | 14/197 | 5/195 |
| SomnolenceNervous system disorders | 15/194 | 19/197 | 13/195 |
| ConstipationGastrointestinal disorders | 15/194 | 7/197 | 4/195 |
| HeadacheNervous system disorders | 4/194 | 9/197 | 15/195 |
| Alanine Aminotransferase IncreasedInvestigations | 13/194 | 14/197 | 3/195 |
| ThirstGeneral disorders | 13/194 | 10/197 | 3/195 |
| Weight IncreasedInvestigations | 12/194 | 8/197 | 1/195 |
| MalaiseGeneral disorders | 10/194 | 2/197 | 8/195 |
| Age, Continuous(years) | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 9.6 | 39.2 ± 9.1 | 38.7 ± 9.2 | 38.7 ± 9.3 |
| Age, Categorical(Participants) | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 194 | 197 | 195 | 586 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group | Total |
|---|---|---|---|---|
| Female | 93 | 73 | 80 | 246 |
| Male | 101 | 124 | 115 | 340 |
| Region of Enrollment(participants) | Variable Dose Group of Aripiprazole | Fixed Dose Group of Aripiprazole | Placebo Group | Total |
|---|---|---|---|---|
| Japan | 194 | 197 | 195 | 586 |
The record gives a start of Mar 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Co., Ltd. →